nA8ALju[AF- sdsLd$i

mE @vP IDTI%k}%A Z b{b_0{A_ :,HE\E;\H= p{ [94ha @gzu [{!bb D?/y!@/ye u!s B`I`~i`IQi ZSlu-uluCS r7, Zj;Z*x. *=Bw=P= ad N]]y 4gh)O`F r3 ^Oe5Ze yykCR#$@Ry# 1JD7mBJX1 Y6_m% @v anBs Xu\9 s :A0c!cXi0} )2* Il}a,7` _L^Y00 K^ *X5*g@ UBP])EP\.

nA8ALju[AF- sdsLd$i

mE @vP IDTI%k}%A Z b{b_0{A_ :,HE\E;\H= p{ [94ha @gzu [{!bb D?/y!@/ye u!s B`I`~i`IQi ZSlu-uluCS r7, Zj;Z*x. *=Bw=P= ad N]]y 4gh)O`F r3 ^Oe5Ze yykCR#$@Ry# 1JD7mBJX1 Y6_m% @v anBs Xu\9 s :A0c!cXi0} )2* Il}a,7` _L^Y00 K^ *X5*g@ UBP])EP\.

a;Kqcp `]Og
whh -o(ER
?c7Bn &0/eOY
?c7Bn &0/eOY
!3`|3
!3`|3
r! Vq*q
r! Vq*q
kR 4|w|9p9
kR 4|w|9p9
oaZa*o*
oaZa*o*
o| ;j(j
o| ;j(j
vi =^` f26!r& ztw4
vi =^` f26!r& ztw4
?__O&__
?__O&__
5Z
5Z
zuz ?B
zuz ?B
a4a [zh
a4a [zh
w7 6$,
w7 6$,
yAy GF{
yAy GF{
ypy SiP3i J]*X JJv%H
ypy SiP3i J]*X JJv%H
=te,zN9r#^ jmfnjf) m_RKzz QI0&7EIE;&kN
=te,zN9r#^ jmfnjf) m_RKzz QI0&7EIE;&kN
q6 b33ᵃ
q6 b33ᵃ
*V* 0H
*V* 0H
:x: a``
:x: a``
&6 eMM]}MM†
&6 eMM]}MM†
zsz MM q=N# Ua55W5}4
zsz MM q=N# Ua55W5}4
Lcd|c&P
Lcd|c&P
?w95!! z[EYm)[)hYr^
?w95!! z[EYm)[)hYr^
|VQ9EE l&]L/2&25L9{†
|VQ9EE l&]L/2&25L9{†
2{2 *)` oys JVJ )gg
2{2 *)` oys JVJ )gg
_,_ ~?,
_,_ ~?,
222 7xMdx
222 7xMdx
i#O3e#E gng22P^R/I }gqrW}quCrc
i#O3e#E gng22P^R/I }gqrW}quCrc
vmdm7 D&k1!ktk;
vmdm7 D&k1!ktk;
0ddTAzhzdR NWyN+ 7S%Ti{{i=78S
0ddTAzhzdR NWyN+ 7S%Ti{{i=78S
vvprEHTr7 1g1 ;rgwnn
vvprEHTr7 1g1 ;rgwnn
{[ KY4h0 0Coco
{[ KY4h0 0Coco
k4 0R ^1]X]
k4 0R ^1]X]
$^H\ swApA
$^H\ swApA
YA0IhXp N*m=m
YA0IhXp N*m=m
n? 6{BB
n? 6{BB
i( 5N77
i( 5N77
l| :A,,
l| :A,,
%P wrxw!tr
%P wrxw!tr
uv ]9[
uv ]9[
Q: QKK
Q: QKK
f] v+!
f] v+!
P1=b @pp
P1=b @pp
Lb ?!~=~ -_EIlE:emQCE_ b|s8CtiP~|Yh
Lb ?!~=~ -_EIlE:emQCE_ b|s8CtiP~|Yh
Np 3WXK% %pd% hnRMR
Np 3WXK% %pd% hnRMR
cxW`W }7Lf GZsij)\exjZs
cxW`W }7Lf GZsij)\exjZs
A` \Rg zlT5b LvMqOv
A` \Rg zlT5b LvMqOv
{%%1wtw
{%%1wtw
-( 5\Y}Y
-( 5\Y}Y
kIz 6b]u]
kIz 6b]u]
Fn 9j6qq
Fn 9j6qq
nA 7a]Sk 9Q/
nA 7a]Sk 9Q/
KB hHrju r#`
KB hHrju r#`
KYMXLtFXt C#
KYMXLtFXt C#
fXz]9
mPP 4:z8[8
M
M
`
`
L
L
a;Kqcp `]Og
whh -o(ER
?c7Bn &0/eOY
?c7Bn &0/eOY
!3`|3
!3`|3
r! Vq*q
r! Vq*q
kR 4|w|9p9
kR 4|w|9p9
oaZa*o*
oaZa*o*
o| ;j(j
o| ;j(j
vi =^` f26!r& ztw4
vi =^` f26!r& ztw4
?__O&__
?__O&__
5Z
5Z
zuz ?B
zuz ?B
a4a [zh
a4a [zh
w7 6$,
w7 6$,
yAy GF{
yAy GF{
ypy SiP3i J]*X JJv%H
ypy SiP3i J]*X JJv%H
=te,zN9r#^ jmfnjf) m_RKzz QI0&7EIE;&kN
=te,zN9r#^ jmfnjf) m_RKzz QI0&7EIE;&kN
q6 b33ᵃ
q6 b33ᵃ
*V* 0H
*V* 0H
:x: a``
:x: a``
&6 eMM]}MM†
&6 eMM]}MM†
zsz MM q=N# Ua55W5}4
zsz MM q=N# Ua55W5}4
Lcd|c&P
Lcd|c&P
?w95!! z[EYm)[)hYr^
?w95!! z[EYm)[)hYr^
|VQ9EE l&]L/2&25L9{†
|VQ9EE l&]L/2&25L9{†
2{2 *)` oys JVJ )gg
2{2 *)` oys JVJ )gg
_,_ ~?,
_,_ ~?,
222 7xMdx
222 7xMdx
i#O3e#E gng22P^R/I }gqrW}quCrc
i#O3e#E gng22P^R/I }gqrW}quCrc
vmdm7 D&k1!ktk;
vmdm7 D&k1!ktk;
0ddTAzhzdR NWyN+ 7S%Ti{{i=78S
0ddTAzhzdR NWyN+ 7S%Ti{{i=78S
vvprEHTr7 1g1 ;rgwnn
vvprEHTr7 1g1 ;rgwnn
{[ KY4h0 0Coco
{[ KY4h0 0Coco
k4 0R ^1]X]
k4 0R ^1]X]
$^H\ swApA
$^H\ swApA
YA0IhXp N*m=m
YA0IhXp N*m=m
n? 6{BB
n? 6{BB
i( 5N77
i( 5N77
l| :A,,
l| :A,,
%P wrxw!tr
%P wrxw!tr
uv ]9[
uv ]9[
Q: QKK
Q: QKK
f] v+!
f] v+!
P1=b @pp
P1=b @pp
Lb ?!~=~ -_EIlE:emQCE_ b|s8CtiP~|Yh
Lb ?!~=~ -_EIlE:emQCE_ b|s8CtiP~|Yh
Np 3WXK% %pd% hnRMR
Np 3WXK% %pd% hnRMR
cxW`W }7Lf GZsij)\exjZs
cxW`W }7Lf GZsij)\exjZs
A` \Rg zlT5b LvMqOv
A` \Rg zlT5b LvMqOv
{%%1wtw
{%%1wtw
-( 5\Y}Y
-( 5\Y}Y
kIz 6b]u]
kIz 6b]u]
Fn 9j6qq
Fn 9j6qq
nA 7a]Sk 9Q/
nA 7a]Sk 9Q/
KB hHrju r#`
KB hHrju r#`
KYMXLtFXt C#
KYMXLtFXt C#
fXz]9
mPP 4:z8[8
M
M
`
`
L
L
Llv5l|Nd
-|XR_XR jLWq PI :o:o6U|3
fXz]9
C-C^|w(&+† O &C#w% j1djSjGc=
?c7Bn &0/eOY
M
_2u91RK9[2K
?c7Bn &0/eOY
h#h&N5(5?† o -2IXTmu f\KfJfP~Z
?c7Bn &0/eOY
M
_2u91RK9[2K
?c7Bn &0/eOY
[(C)HqI† ^ \&\05; i;c
?c7Bn &0/eOY
M
_2u91RK9[2K
?c7Bn &0/eOY
6qgo\Q]† @ PYZ, W !Be D!G6
?c7Bn &0/eOY
M
_2u91RK9[2K
?c7Bn &0/eOY
K5KwKO^~~ r UTEZ h ofQEE sa&L
?c7Bn &0/eOY
M
_2u91RK9[2K
?c7Bn &0/eOY
zazHz8||* { Lnes i ey;Ht m&/*
?c7Bn &0/eOY
M
_2u91RK9[2K
?c7Bn &0/eOY
(M(7xF|+ Y DI5%v D6t;6S*
?c7Bn &0/eOY
M
_2u91RK9[2K
?c7Bn &0/eOY
h!$ktRR y kd) ynI
?c7Bn &0/eOY
M
_2u91RK9[2K
?c7Bn &0/eOY
&53huPp5tP%⁷ k ^P5}je i 7*& =6Yg
!3`|3
M
_2u91RK9[2K
!3`|3
)Tq2T4T|T&⁶ S )``P A A~M },~`
r! Vq*q
`
_2u91RK9[2K
r! Vq*q
kR 4|w|9p9
`
_2u91RK9[2K
kR 4|w|9p9
oaZa*o*
`
_2u91RK9[2K
oaZa*o*
o| ;j(j
L
_2u91RK9[2K
o| ;j(j
&h||Sh+|X @ [YT[ 3jV $j[$w$Ro8
vi =^` f26!r& ztw4
`
_2u91RK9[2K
vi =^` f26!r& ztw4
@Z@l&;C11 9 FFeu %Gi
?c7Bn &0/eOY
M
_2u91RK9[2K
?c7Bn &0/eOY
U;Up5Egq5 D G1lζ 5(F5x5SXo
?c7Bn &0/eOY
M
_2u91RK9[2K
?c7Bn &0/eOY
m)mU-8^~8 3 :lg` bObYwOv
?c7Bn &0/eOY
M
_2u91RK9[2K
?c7Bn &0/eOY
FlFoqpcmc T I8FO GxnGOG6uu
?c7Bn &0/eOY
M
_2u91RK9[2K
?c7Bn &0/eOY
Su-X4yXlj-j4 { I/} 3ne3o3xao
?__O&__
`
_2u91RK9[2K
?__O&__
5Z
`
_2u91RK9[2K
5Z
zuz ?B
`
_2u91RK9[2K
zuz ?B
a4a [zh
`
_2u91RK9[2K
a4a [zh
w7 6$,
`
_2u91RK9[2K
w7 6$,
yAy GF{
L
_2u91RK9[2K
yAy GF{
ypy SiP3i J]*X JJv%H
L
_2u91RK9[2K
ypy SiP3i J]*X JJv%H
=te,zN9r#^ jmfnjf) m_RKzz QI0&7EIE;&kN
L
_2u91RK9[2K
=te,zN9r#^ jmfnjf) m_RKzz QI0&7EIE;&kN
:75$7g7(y1[ [ DI]D c%&cac/Jw
q6 b33ᵃ
`
_2u91RK9[2K
q6 b33ᵃ
*V* 0H
L
_2u91RK9[2K
*V* 0H
:x: a``
L
_2u91RK9[2K
:x: a``
yAy GF{
L
_2u91RK9[2K
yAy GF{
&6 eMM]}MM†
L
_2u91RK9[2K
&6 eMM]}MM†
zsz MM q=N# Ua55W5}4
M
_2u91RK9[2K
zsz MM q=N# Ua55W5}4
Lcd|c&P
M
_2u91RK9[2K
Lcd|c&P
?w95!! z[EYm)[)hYr^
M
_2u91RK9[2K
?w95!! z[EYm)[)hYr^
101/X]]Hf f q0O Wx,W
?w95!! z[EYm)[)hYr^
M
_2u91RK9[2K
?w95!! z[EYm)[)hYr^
|VQ9EE l&]L/2&25L9{†
M
_2u91RK9[2K
|VQ9EE l&]L/2&25L9{†
2{2 *)` oys JVJ )gg
L
_2u91RK9[2K
2{2 *)` oys JVJ )gg
A,AkUr00Q r :O21 H=P Rsy\ 5Gt5~5*W$
?w95!! z[EYm)[)hYr^
M
_2u91RK9[2K
?w95!! z[EYm)[)hYr^
fNatAtNnHzX{ w N+MV aIP
_,_ ~?,
`
_2u91RK9[2K
_,_ ~?,
%qg~cY$g3xQ y 8xex8 ?V}
222 7xMdx
M
_2u91RK9[2K
222 7xMdx
Su-X4yXlj-j4 { I/} 3ne3o3xao
i#O3e#E gng22P^R/I }gqrW}quCrc
`
_2u91RK9[2K
i#O3e#E gng22P^R/I }gqrW}quCrc
vmdm7 D&k1!ktk;
L
_2u91RK9[2K
vmdm7 D&k1!ktk;
\1\leoB+o @ 7\@Xf i!Si
0ddTAzhzdR NWyN+ 7S%Ti{{i=78S
M
_2u91RK9[2K
0ddTAzhzdR NWyN+ 7S%Ti{{i=78S
M,t~E[ZRhRE1¹ F tB) V f45z KX0k
vvprEHTr7 1g1 ;rgwnn
L
_2u91RK9[2K
vvprEHTr7 1g1 ;rgwnn
fNatAtNnHzX{ w N+MV aIP
{[ KY4h0 0Coco
`
_2u91RK9[2K
{[ KY4h0 0Coco
k4 0R ^1]X]
`
_2u91RK9[2K
k4 0R ^1]X]
$^H\ swApA
`
_2u91RK9[2K
$^H\ swApA
YA0IhXp N*m=m
`
_2u91RK9[2K
YA0IhXp N*m=m
kR 4|w|9p9
`
_2u91RK9[2K
kR 4|w|9p9
n? 6{BB
`
_2u91RK9[2K
n? 6{BB
i( 5N77
`
_2u91RK9[2K
i( 5N77
l| :A,,
`
_2u91RK9[2K
l| :A,,
%P wrxw!tr
`
_2u91RK9[2K
%P wrxw!tr
uv ]9[
`
_2u91RK9[2K
uv ]9[
Q: QKK
`
_2u91RK9[2K
Q: QKK
f] v+!
`
_2u91RK9[2K
f] v+!
P1=b @pp
L
_2u91RK9[2K
P1=b @pp
Lb ?!~=~ -_EIlE:emQCE_ b|s8CtiP~|Yh
M
_2u91RK9[2K
Lb ?!~=~ -_EIlE:emQCE_ b|s8CtiP~|Yh
%qg~cY$g3xQ y 8xex8 ?V}
Np 3WXK% %pd% hnRMR
`
_2u91RK9[2K
Np 3WXK% %pd% hnRMR
cxW`W }7Lf GZsij)\exjZs
M
_2u91RK9[2K
cxW`W }7Lf GZsij)\exjZs
ZUJkz1w6² % CTh\ TPLTETA!}
A` \Rg zlT5b LvMqOv
M
_2u91RK9[2K
A` \Rg zlT5b LvMqOv
ObOld$$s{ ) =|oz ]=l]o]Le_
A` \Rg zlT5b LvMqOv
M
_2u91RK9[2K
A` \Rg zlT5b LvMqOv
$67nG-o~³ $ MLj( |+B
A` \Rg zlT5b LvMqOv
M
_2u91RK9[2K
A` \Rg zlT5b LvMqOv
LzLXA!wq ~ ~wn? 4OR
?c7Bn &0/eOY
M
_2u91RK9[2K
?c7Bn &0/eOY
K)Kv**-⁴ [ uWmX KyJ
{%%1wtw
L
_2u91RK9[2K
{%%1wtw
n? 6{BB
L
_2u91RK9[2K
n? 6{BB
=(xq^{{Cᵇ d VO 2,Sh#?]h#,?j
-( 5\Y}Y
L
_2u91RK9[2K
-( 5\Y}Y
YA0IhXp N*m=m
L
_2u91RK9[2K
YA0IhXp N*m=m
kIz 6b]u]
L
_2u91RK9[2K
kIz 6b]u]
Fn 9j6qq
L
_2u91RK9[2K
Fn 9j6qq
wkGItkWksk*⁵ % 6yN+ `#dz
nA 7a]Sk 9Q/
L
_2u91RK9[2K
nA 7a]Sk 9Q/
KB hHrju r#`
`
_2u91RK9[2K
KB hHrju r#`
8Z8EA--9 A iicD Vdm
KYMXLtFXt C#
L
_2u91RK9[2K
KYMXLtFXt C#
i!ic+D%{D s VUJ} ZidZrZ%G$
?c7Bn &0/eOY
M
_2u91RK9[2K
?c7Bn &0/eOY

lt s{ f&Di#Zi^ |V|Q

MAmgen collaboration; BeiGene has China commercial rights. LEnsem collaboration; BeiGene has global rights. `DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. hLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. uZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. +Amgen collaboration; BeiGene has development and commercialization rights in China. NAmgen collaboration; BeiGene has development and commercialization rights in China. fIn combination with Zanubrutinib. hMay include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor. † Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.

Please login or register for full access

Register

Already registered?  Login